Jubilant Pharmova Ltd

Jubilant Pharmo Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jubilant Pharmova Ltd

₹ 990 0.13%
21 May 2:24 p.m.
jubl.com BSE: 530019 NSE: JUBLPHARMA
About

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

Key Points

Business Segments & Revenue Contribution 9MFY24[1][2]
a) Radiopharma (~44%): Radiopharmaceuticals (including radiopharmacies)The company is the #3 radiopharmaceutical manufacturer in the US and has the #2 network in the US with 46 radiopharmacies. In 9MFY24, sale of Mertiatide, Sulfur colloid) and Ruby-Fill did very well. RUBY-FILL is a cardiac imaging product. Company plans to maintain its leadership position in North America.[3]

Website BSE NSE
  • Market Cap ₹ 15,776 Cr.
  • Current Price ₹ 990
  • High / Low ₹ 1,310 / 617
  • Stock P/E 28.5
  • Book Value ₹ 393
  • Dividend Yield 0.48 %
  • ROCE 9.54 %
  • ROE 9.50 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company's working capital requirements have reduced from 59.9 days to 30.2 days

Cons

  • Stock is trading at 2.54 times its book value
  • The company has delivered a poor sales growth of 3.90% over past five years.
  • Company has a low return on equity of 1.36% over last 3 years.
  • Company might be capitalizing the interest cost
  • Earnings include an other income of Rs.416 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
1,528 1,452 1,600 1,552 1,678 1,587 1,680 1,677 1,759 1,732 1,752 1,822 1,929
1,280 1,259 1,384 1,408 1,459 1,419 1,438 1,459 1,487 1,480 1,463 1,535 1,584
Operating Profit 247 192 216 144 219 168 242 218 271 252 289 287 345
OPM % 16% 13% 14% 9% 13% 11% 14% 13% 15% 15% 17% 16% 18%
-2 11 -44 10 21 9 19 49 -151 410 8 -10 9
Interest 40 40 42 51 56 62 66 71 73 71 61 56 53
Depreciation 101 95 94 94 271 90 97 95 101 91 91 91 95
Profit before tax 106 69 36 9 -86 25 98 101 -54 500 144 130 206
Tax % 44% 32% 87% 285% 16% 76% 37% 34% 15% 4% 29% 23% 27%
59 47 5 -16 -100 6 62 66 -62 482 102 101 151
EPS in Rs 3.74 2.96 0.34 -0.98 -6.15 0.40 3.92 4.19 -3.68 30.26 6.45 6.33 9.64
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
5,762 5,751 5,749 5,861 7,518 9,111 5,976 6,099 6,130 6,282 6,703 7,234
4,763 5,141 4,493 4,510 5,995 7,367 4,428 4,695 4,980 5,503 5,802 6,061
Operating Profit 999 610 1,256 1,352 1,522 1,744 1,548 1,403 1,150 779 901 1,173
OPM % 17% 11% 22% 23% 20% 19% 26% 23% 19% 12% 13% 16%
-173 86 4 19 36 -249 225 263 8 -9 -76 416
Interest 337 368 371 341 284 220 200 184 145 188 272 240
Depreciation 281 288 347 291 415 371 340 349 382 554 382 369
Profit before tax 207 40 542 738 859 904 1,233 1,133 630 28 170 981
Tax % 34% 200% 29% 22% 26% 36% 27% 26% 34% 333% 57% 15%
138 -40 387 575 634 577 898 836 413 -65 73 836
EPS in Rs 6.84 -3.63 24.60 36.14 40.35 36.06 56.39 52.47 25.98 -3.83 4.84 52.69
Dividend Payout % 43% -83% 12% 8% 7% 12% 9% 10% 19% -130% 102% 9%
Compounded Sales Growth
10 Years: 2%
5 Years: 4%
3 Years: 6%
TTM: 8%
Compounded Profit Growth
10 Years: 27%
5 Years: -10%
3 Years: 10%
TTM: 1257%
Stock Price CAGR
10 Years: 21%
5 Years: 19%
3 Years: 34%
1 Year: 41%
Return on Equity
10 Years: 10%
5 Years: 6%
3 Years: 1%
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 15 16 16 16 16 16 16 16 16 16 16 16
Reserves 2,611 2,438 2,951 3,420 4,071 4,793 5,588 4,726 5,303 5,383 5,418 6,239
4,395 4,793 4,493 4,045 3,469 4,840 4,808 2,830 3,192 3,677 3,664 2,731
1,842 1,372 1,280 1,417 1,902 1,670 1,898 1,192 1,319 1,853 2,240 3,770
Total Liabilities 8,864 8,619 8,740 8,899 9,457 11,319 12,310 8,763 9,830 10,929 11,338 12,756
5,099 4,911 5,104 5,107 5,401 5,648 6,340 4,609 4,871 5,183 5,091 6,091
CWIP 472 597 611 684 671 901 768 897 1,090 1,562 2,103 2,715
Investments 34 40 85 103 124 115 69 241 239 256 42 44
3,259 3,071 2,939 3,006 3,262 4,654 5,133 3,017 3,631 3,928 4,101 3,907
Total Assets 8,864 8,619 8,740 8,899 9,457 11,319 12,310 8,763 9,830 10,929 11,338 12,756

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
772 783 1,099 1,268 1,303 1,122 1,543 1,784 838 661 971 1,072
-164 -362 -309 -465 -614 -1,018 -267 -727 -323 -474 -596 488
-414 -503 -843 -686 -901 657 -1,050 -1,709 -33 -157 -432 -1,453
Net Cash Flow 194 -82 -52 117 -212 761 225 -652 482 30 -58 107

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 51 52 60 63 55 51 79 49 55 56 50 45
Inventory Days 200 169 207 223 177 147 463 268 308 268 220 178
Days Payable 107 99 106 137 145 106 273 124 139 160 146 158
Cash Conversion Cycle 144 122 162 149 87 92 268 194 224 165 124 65
Working Capital Days -16 45 52 66 57 65 105 78 86 77 72 30
ROCE % 11% 6% 13% 15% 15% 16% 15% 12% 10% 3% 7% 10%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
50.68% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67%
23.47% 23.06% 23.38% 23.22% 23.20% 23.20% 20.29% 19.06% 19.50% 17.94% 16.96% 17.23%
0.62% 1.60% 1.62% 1.62% 1.63% 1.64% 2.89% 3.77% 4.06% 5.66% 6.99% 7.05%
0.00% 0.00% 0.00% 1.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
25.17% 24.59% 24.20% 23.11% 23.91% 23.89% 25.56% 25.91% 25.18% 25.17% 24.82% 24.48%
0.07% 0.07% 0.13% 0.13% 0.59% 0.59% 0.58% 0.58% 0.58% 0.56% 0.56% 0.56%
No. of Shareholders 1,09,4101,05,6321,00,21297,93593,37589,37686,58892,26481,99289,4561,02,44296,526

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls